Compared to Estimates, Halozyme Therapeutics (HALO) Q2 Earnings: A Look at Key Metrics

For the quarter ended June 2024, Halozyme Therapeutics (HALO) reported revenue of $231.35 million, up 4.7% over the same period last year. EPS came in at $0.91, compared to $0.74 in the year-ago quarter. The reported revenue compares to the Zacks Consensus Estimate of $210.92 million, representing a surprise of +9.69%. The company delivered an EPS surprise of +16.67%, with the consensus EPS estimate being $0.78. While investors scrutinize revenue and earnings changes year-over-year and how they compare with ...